Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
ATENOLOL
TEVA CANADA LIMITED
C07AB03
ATENOLOL
50MG
TABLET
ATENOLOL 50MG
ORAL
100/500
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0113847002; AHFS:
APPROVED
2002-05-15
_TEVA ATENOLOL (Atenolol) _ _ _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-ATENOLOL Atenolol Tablets Tablets, 50 mg and 100 mg, Oral B.P. Beta-adrenergic receptor blocking agent Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada, M1B 2K9 www.tevacanada.com Submission Control Number: 278032 Date of Initial Authorization: NOV 22, 2017 Date of Revision: FEB 16, 2024 _TEVA ATENOLOL (Atenolol) _ _ _ _Page 2 of 32 _ RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS………………………………………………………………………………………………………………2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................ 4 1 INDICATIONS .......................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................. 4 1.2 Geriatrics ............................................................................................................................. 4 2 CONTRAINDICATIONS ............................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................................... 5 4 DOSAGE AND ADMINISTRATION ........................................................................................ 5 4.1 Dosing Considerations ..................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ………………………………………………………………5 4.4 Administration ... Đọc toàn bộ tài liệu